TABLE 2.
Comparison of the SAMBA semi-Q and Roche TaqMan v2 results for 488 clinical samples from London (n = 134), Malawi (n = 200), and Uganda (n = 154)a
| Sample source and SAMBA Semi-Q result (copies/ml) | No. with result with Roche TaqMan v2 (copies/ml) |
|
|---|---|---|
| <1,000 | >1,000 | |
| London | ||
| <1,000 | 95 | 1 |
| >1,000 | 2 | 36 |
| Malawi | ||
| <1,000 | 146 | 0 |
| >1,000 | 4 | 50 |
| Uganda | ||
| <1,000 | 91 | 5 |
| >1,000 | 3 | 55 |
a
Concordance between the two tests was 96.9% (473/488) overall, 97.8% (131/134) in London, 98.0% (196/200) in Malawi, and 94.8% (146/154) in Uganda.